Lynparza 100mg Tablet is an anticancer drug belonging to the category of poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, containing the active ingredient Olaparib. It is used to treat pancreatic, and prostate cancer. Cancer is a disease in which cells multiply uncontrollably and abnormally. This medication can be given alone or in combination with other anticancer medications.

Speak with your doctor immediately if you experience breathlessness, chest pain, rapid heart rate, fever, cough, or wheezing. Your healthcare provider will conduct blood tests before and every month during the treatment, as this medicine could reduce the counts of RBC, WBC, and platelets. Tell your healthcare provider before starting treatment, if you have been diagnosed with problems in your lungs, liver, heart, or kidneys. 

This drug is not recommended during pregnancy as it might harm the unborn baby and lead to miscarriage. Hence, it is advisable to do a pregnancy test before starting this treatment for women of childbearing age. Ideally, it is better to continue birth control methods for a minimum of 6 months after completion of the treatment. Avoid breastfeeding your baby while you are on the treatment, as it is unknown whether Lynparza 100mg Tablet passes into the breast milk.

Lynparza 100mg Tablet is used to treat,

• Prostate cancer
• Pancreatic cancer

Lynparza 100mg Tablet works by inhibiting PARP enzymes, blocks the repair of single-stranded DNA, and ultimately hinders the growth and development of cancer cells.

Inform your healthcare provider about all the medicines you take, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Lynparza 100mg Tablet and reduce effectiveness by causing undesirable side effects.

• Store Lynparza 100mg Tablet in the original package at room temperature (20°C to 25°C).
• Keep it out of reach from children.

The medicine will be prescribed to you by a healthcare professional in a hospital setting. Lynparza 100mg is available as a tablet to be taken with or without food, as directed by your healthcare provider. The usual recommended dosage is 250 mg tablet once daily. Avoid crushing, opening, or dissolving the tablet; swallow it whole with a glass of water. Take the tablet at the same time every day.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

 Common

• diarrhea
• nausea
• vomiting
• loss of appetite
• weakness
• red or sore mouth
• increased liver enzymes
• itchy or cracked skin
• dry mouth
• red or itchy eyes
• nail problems
• hair loss
• fever
• blood in the urine and a burning sensation while urinating

Lynparza 100mg Tablet can reduce blood cell counts, so it is advisable to be prompt during blood check-ups. Avoid direct exposure to sunlight during this therapy, and apply sunscreen above SPF 50 before stepping out. Do not stop taking this drug without consulting your doctor. Avoid grapefruit juice during treatment with this drug since it may increase the drug concentration level in your blood.

1. AstraZeneca UK Limited, Electronic medicines compendium (EMC), [Revised on Jan 2021] [ Accessed on 10 May 2023], https://www.medicines.org.uk/emc/files/pil.9204.pdf
2. AstraZeneca Pharmaceuticals LP, US Food and Drug Administration, [Revised on Jan 2018] [Accessed on 10 May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf
3. Sylvia Bochum, Stephanie Berger, Uwe M Martens; Olaparib; Recent Results in Cancer Research; Published on 2018; [Accessed on 10 May 2023] https://pubmed.ncbi.nlm.nih.gov/30069770/
4. Xiao Xia Guo et al.; The efficacy and safety of the drug Olaparib in the treatment of cancers: a meta-analysis of randomized controlled drug trials; Cancer Management and Research; Published on Aug 2018;[Accessed on 10 May 2023] https://pubmed.ncbi.nlm.nih.gov/30127642/
5. Sebastiaan C. Goulooze et al, Olaparib, Br J Clin Pharmaco, 81:1, 171-173, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693566/pdf/BCP-81-171.pdf